Sharara AI et al. |
Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238584
|
Graham DY and Gisbert JP |
Letter: clarithromycin dose for H. pylori therapy remains unresolved. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238583
|
Kositchaiwat C et al. |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616168
|
Datta S et al. |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963080
|
Lamouliatte H et al. |
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535872
|
Gisbert JP and Calvet X |
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22129228
|
Laine L et al. |
Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768532
|
Malfertheiner P et al. |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860399
|
Vakil N et al. |
Seven-day therapy for Helicobacter pylori in the United States. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15225176
|
Mason J et al. |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876711
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Elizalde JI et al. |
Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876713
|
Goddard AF et al. |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233187
|
Pilotto A et al. |
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233191
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Ford AC et al. |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17944741
|
Xiao SD et al. |
A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11136281
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Armuzzi A et al. |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11148433
|
Zamani M et al. |
Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074507
|